These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 16160485)

  • 1. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
    Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S
    Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transformation of Hodgkin's disease to high-grade B-cell lymphoma: remission after Rituximab monotherapy.
    Kirchner EM; Ebsen M; Kirchner J; Theegarten D; Voigtmann R
    Ann Oncol; 2001 Aug; 12(8):1169-71. PubMed ID: 11583202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diffuse large B-cell lymphoma following nodular lymphocyte predominant Hodgkin's lymphoma: report of a case].
    Chen DB; Wang Y; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):635-6. PubMed ID: 21092597
    [No Abstract]   [Full Text] [Related]  

  • 4. Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab.
    Natkunam Y; Stanton TS; Warnke RA; Horning SJ
    Clin Lymphoma; 2001 Dec; 2(3):185-7. PubMed ID: 11779297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma].
    Liu YH; Zhuang HG; Lin HL; Wu QL; Luo DL; Li L; Luo XL
    Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):594-8. PubMed ID: 17243292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?
    Fanale M
    Hematology Am Soc Hematol Educ Program; 2013; 2013():406-13. PubMed ID: 24319212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl.
    Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S
    Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.
    Clarke LE; Bayerl MG; Ehmann WC; Helm KF
    J Cutan Pathol; 2003 Aug; 30(7):459-62. PubMed ID: 12859745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
    Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
    Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
    Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S
    Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
    Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
    Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.
    Menke JR; Spinner MA; Natkunam Y; Warnke RA; Advani RH; Gratzinger DA
    Arch Pathol Lab Med; 2021 Jun; 145(6):753-758. PubMed ID: 32991677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
    Seliem RM; Freeman JK; Steingart RH; Hasserjian RP
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
    Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
    J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD20-Positive peripheral T-cell lymphoma: report of a case after nodular sclerosis Hodgkin's disease and review of the literature.
    Mohrmann RL; Arber DA
    Mod Pathol; 2000 Nov; 13(11):1244-52. PubMed ID: 11106083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell/histiocyte-rich large B-cell lymphoma is a disseminated aggressive neoplasm: differential diagnosis from Hodgkin's lymphoma.
    Fraga M; Sánchez-Verde L; Forteza J; García-Rivero A; Piris MA
    Histopathology; 2002 Sep; 41(3):216-29. PubMed ID: 12207783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
    Maeda LS; Advani RH
    Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
    Davis TA; Czerwinski DK; Levy R
    Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.